Valuation: DiaSorin S.p.A.

Market Cap 3.54B 4.03B 3.29B 3.03B 5.67B 390B 5.78B 39.34B 15.35B 190B 15.12B 14.79B 660B P/E 2026 *
19.3x
P/E 2027 * 17x
Enterprise Value 4.21B 4.79B 3.91B 3.6B 6.75B 464B 6.87B 46.78B 18.24B 226B 17.97B 17.58B 785B EV / Sales 2026 *
3.43x
EV / Sales 2027 * 3.13x
Free-Float
37.17%
Yield 2026 *
1.96%
Yield 2027 * 2.05%
1 day-0.39%
1 week-3.25%
Current month-1.02%
1 month+0.89%
3 months+12.16%
6 months-5.93%
Current year-2.43%
1 week 66.22
Extreme 66.22
70.4
1 month 66.1
Extreme 66.1
71.4
Current year 51.14
Extreme 51.14
77.58
1 year 51.14
Extreme 51.14
92.36
3 years 51.14
Extreme 51.14
112.1
5 years 51.14
Extreme 51.14
208.7
10 years 30.74
Extreme 30.7396
211.8
Manager TitleAgeSince
Chief Executive Officer 60 26/03/2007
Director of Finance/CFO - 01/01/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 60 28/04/2016
Director/Board Member 63 26/03/2007
Chairman 57 29/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-3.25% - - 4.03B
-1.52%-5.28%+224.55%+299.24% 19.92B
+0.72%-4.79%-44.67%-27.15% 9.25B
+1.20%-3.38%+46.56%+23.13% 6.75B
-4.00%+5.85%+237.22%-22.65% 6.1B
-1.59%+5.91%-12.16%-23.02% 5.53B
-10.00%+2.06%+88.80%+110.73% 4.55B
-1.79%-7.34%-48.19% - 4.42B
-1.68%-2.81%-16.61%-39.76% 2.71B
+0.92%-13.04%-32.46%+204.93% 1.62B
Average -1.78%-1.18%+49.23%+65.68% 6.76B
Weighted average by Cap. -1.62%-1.60%+96.08%+112.10%

Financials

2026 *2027 *
Net sales 1.23B 1.39B 1.14B 1.05B 1.97B 135B 2B 13.63B 5.32B 65.89B 5.24B 5.12B 229B 1.3B 1.48B 1.21B 1.11B 2.09B 144B 2.13B 14.49B 5.65B 70.07B 5.57B 5.45B 243B
Net income 182M 207M 169M 156M 292M 20.08B 297M 2.03B 790M 9.79B 778M 762M 33.98B 205M 233M 191M 175M 329M 22.59B 335M 2.28B 889M 11.02B 876M 857M 38.23B
Net Debt 669M 761M 622M 572M 1.07B 73.67B 1.09B 7.43B 2.9B 35.93B 2.86B 2.79B 125B 539M 613M 501M 461M 864M 59.38B 880M 5.99B 2.34B 28.97B 2.3B 2.25B 100B
Logo DiaSorin S.p.A.
DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc. At the end of 2025, the group had 9 production sites located in Italy, the United States (4), Canada, Germany, the United Kingdom and Chine. Net sales are distributed geographically as follows: Italy (15.2%), Europe (24.9%), North America (51.8%), and other (8.1%).
Employees
3,242
Date Price Change Volume
24/07/26 67.07 -0.09% 0
23/07/26 €66.82 -0.27% 7,436
22/07/26 €67.00 -0.62% 12,014
21/07/26 €67.42 -3.96% 25,211
20/07/26 €70.20 +1.27% 6,581
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
66.82EUR
Average target price
70.45EUR
Spread / Average Target
+5.43%

Quarterly revenue - Rate of surprise